

Call for Speakers:

2026 ASH Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure

Friday, December 11, 2026, 3:00 pm – 6:00 pm CT, New Orleans, Louisiana

We invite you to submit a description of your talk to be considered for a speaking slot at the 2026 Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure.

To submit, please use the submission link below and complete your description **latest by Monday, August 10th, 6pm EST.** Please submit as early as possible as space is limited.

Submission link: <https://forms.cloud.microsoft/r/Be5RiEYTa6>

Workshop Co-Chairs

Lucy Fox, MBBS, BCom/BSc, FRACP, FRCPA, DMedSc
Peter MacCallum Cancer Centre
Melbourne, Australia (lucy.fox@petermac.org)

Marcin Wlodarski, MD, PhD
St. Jude Children's Research Hospital
Memphis, TN (marcin.wlodarski@stjude.org)

Workshop Sessions

Please indicate in your submission the session most relevant to your talk.

Session 1: Diseases and Mechanisms

(Moderators: Sushree Sahoo, PhD & Timothy Chlon, PhD)

This overarching session will explore newly characterized germline predisposition disorders and the mechanisms by which deleterious germline variants drive abnormal hematopoiesis, bone marrow failure, and progression to malignancy. Talks will integrate genetic, biochemical, cellular, and model-organism approaches to illuminate disease pathophysiology and identify shared and disorder-specific vulnerabilities that may guide future therapeutic strategies.

Session 2: Precision Genomic Medicines in BMF

(Moderators: Deena Iskander, M.D., Ph.D., FRCPath & Kristen Schratz, MD)

This focused session will examine how precision genomic approaches, including gene therapy, gene editing, and small molecules, are being developed and applied for germline HM/BMF disorders. Talks will cover preclinical studies and emerging clinical experience and will highlight the unique considerations of delivering precision therapies to patients with germline disorders.

Session 3: Novel Insights in Molecular Surveillance

(Moderators: Felicia Andresen, MD, PhD & Ing-Soo Tiong, MBBS, FRACP, FRCPA, PhD)

This focused session will discuss recent advances in the molecular surveillance of individuals carrying germline predisposition variants. Talks will address the application of high-sensitivity sequencing and clonal-tracking technologies, the natural history and clinical significance of clonal hematopoiesis arising on a germline-predisposed background, and emerging frameworks for using molecular data to guide pre-emptive intervention and stratify malignancy risk.

Session 4: New Discoveries

(Moderators: Harry Layton Lesmana, MD & Sara Torres-Esquiú, MS, GCP)

This overarching session will highlight new scientific discoveries in germline predisposition to HMs and BMF, including newly recognized disease genes and syndromes, novel insights in established disorders, and new knowledge from variant curation efforts and guideline groups.